Stocks Health care RCUS
NYSE · Health careArcus Biosciences, Inc. (RCUS)
Arcus Biosciences, Inc. brought in $100M of revenue over the twelve months to September 30, 2026, down 58.3% from a year earlier. It posted a net loss of $453M. In fiscal 2025 capital spending exceeded operating cash flow by $484M. At September 30, 2026 it held $151M in cash against $102M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 4, 2026.
Key facts about Arcus Biosciences, Inc.
- Net worth
- Arcus Biosciences, Inc. has a market value (market cap) of $2.4B at the latest share price, and shareholders' equity of $358M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $247M (-4.3% year on year), with a net loss of $353M. Over the 12 months to September 30, 2026: revenue $100M, net loss $453M.
- Cash flow
- In fiscal 2025 operations used $482M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 4, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Arcus Biosciences, Inc.'s next report is expected around February 24, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Arcus Biosciences, Inc. does
Arcus Biosciences, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NYSE under the ticker RCUS.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $247M | -$353M | -$3.29 | -$484M |
| 2024 | $258M | -$283M | -$3.14 | -$176M |
| 2023 | $117M | -$307M | -$4.15 | -$330M |
| 2022 | $112M | -$267M | -$3.71 | $432M |
| 2021 | $383M | $53M | $0.71 | -$282M |
| 2020 | $78M | -$123M | -$2.24 | $108M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where RCUS ranks in Health care
Latest SEC filings
What Arcus Biosciences, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 4, 2026Quarterly report 10-Q · period to September 30, 2026Revenue fell 65% to $9M versus the same quarter last year; diluted EPS -$1.00 versus -$1.27.
- November 4, 2026
- October 23, 2026Other event 8-K
- October 21, 2026
- October 20, 2026Other event 8-K
- August 5, 2026Quarterly report 10-Q · period to June 30, 2026Revenue fell 74% to $41M versus the same quarter last year; diluted EPS -$0.72 versus $0.00.
- August 5, 2026
- June 12, 2026
- May 5, 2026Quarterly report 10-Q · period to March 31, 2026Revenue fell 39% to $17M versus the same quarter last year; diluted EPS -$1.02 versus -$1.14.
- May 5, 2026
Insider trades
What the people running Arcus Biosciences, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $84.8K worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| August 21, 2026 | Azoy AlexanderChief Accounting Officer | Exercised options | 2,827 | $43.6K |
| August 21, 2026 | Azoy AlexanderChief Accounting Officer | Soldpre-planned (10b5-1) | 2,827 | $84.8K |
| July 10, 2026 | Jaen Juan C.President | Soldpre-planned (10b5-1), indirect | 19,799 | $566.4K |
| July 10, 2026 | Jaen Juan C.President | Soldpre-planned (10b5-1), indirect | 268 | $7.9K |
| July 9, 2026 | Jaen Juan C.President | Soldpre-planned (10b5-1), indirect | 48,502 | $1.5M |
| June 24, 2026 | Jaen Juan C.President | Soldpre-planned (10b5-1), indirect | 6,431 | $190.7K |
| June 23, 2026 | Jaen Juan C.President | Soldpre-planned (10b5-1), indirect | 14,067 | $389.5K |
| June 23, 2026 | Jaen Juan C.President | Soldpre-planned (10b5-1), indirect | 1,697 | $47.6K |
Who owns RCUS
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
Largest institutional holders
Insiders
14 insiders reported holding 4,384,258 shares in total, about $81.6M at the last price.
| Holder | Shares |
|---|---|
| Rosen Terry JChief Executive Officer, Director | 2,236,409 |
| Jaen Juan C.President | 1,199,252822,240 held indirectly |
| Jarrett JenniferChief Operating Officer | 224,024 |
| Tang Carolyn C.General Counsel | 184,607 |
| Markus RichardChief Medical Officer | 89,647 |
| Goeltz II Robert C.Chief Financial Officer | 84,161 |
| Lacey David L.Director | 76,652 |
| Perlman Andrew JDirector | 48,325 |
| Falberg Kathryn EDirector | 44,300 |
| Machado PatrickDirector | 44,300 |
Questions about RCUS
What does Arcus Biosciences, Inc. do?
Arcus Biosciences, Inc. is a company in the Health care sector, listed on NYSE as RCUS. Its shares trade on NYSE under the ticker RCUS.
What is Arcus Biosciences, Inc.'s net worth?
Arcus Biosciences, Inc. has a market value (market cap) of $2.4B at the latest share price, and shareholders' equity of $358M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Arcus Biosciences, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $453M on revenue of $100M.
How much revenue does Arcus Biosciences, Inc. make?
Over the twelve months to September 30, 2026 Arcus Biosciences, Inc. reported revenue of $100M. That is 58.3% less than a year earlier.
When did Arcus Biosciences, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 4, 2026. It covers the period to September 30, 2026.
When is Arcus Biosciences, Inc.'s next earnings report?
Arcus Biosciences, Inc.'s next report is expected around February 24, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare RCUS with
Follow RCUS
Get an email when Arcus Biosciences, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Arcus Biosciences, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.